NCT05263570View on ClinicalTrials.gov

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

RecruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Standard Therapy

Standard Therapy, including TCbHP, THP, EC-THP, AC-THP

Trial Locations (1)

110004

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors

lead

Shengjing Hospital

OTHER